<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2930">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068754</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14042068</org_study_id>
    <nct_id>NCT03068754</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, multiple dose study to examine the effect of H.P. Acthar® (Acthar) on
      functional decline in adult subjects with amyotrophic lateral sclerosis (ALS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, multiple dose study to examine the effect of Acthar on functional
      decline in adult subjects with amyotrophic lateral sclerosis (ALS). Approximately 195
      subjects will be enrolled.

      Following a screening period of up to 28 days, subjects with ALS and symptom onset (defined
      as first muscle weakness or dysarthria) ≤ 2 years prior to the Screening Visit will be
      randomized on a 2:1 basis to receive subcutaneous (SC) Acthar 0.2 mL (16 Units [U]) daily
      (QD) or SC matching placebo 0.2 mL QD for 36 weeks, followed by a 3 week taper.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Telephone administered Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Change from baseline in telephone administered ALSFRS-R</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Telephone administered ALSFRS-R total score decline</measure>
    <time_frame>36 weeks</time_frame>
    <description>Mean slope of the telephone administered ALSFRS-R total score decline from baseline in the group treated with Acthar vs the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator administered ALSFRS-R total score decline</measure>
    <time_frame>36 weeks</time_frame>
    <description>Mean slope of investigator administered ALSFRS-R total score decline from baseline in the group treated with Acthar vs the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telephone administered ALSFRS-R total score and investigator administered ALSFRS-R total score</measure>
    <time_frame>36 weeks</time_frame>
    <description>Change from baseline in telephone administered ALSFRS-R total score and investigator administered ALSFRS-R total score over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function test A: Mean slope of percent predicted forced vital capacity test</measure>
    <time_frame>36 weeks</time_frame>
    <description>Mean slope of percent predicted forced vital capacity test decline from baseline in the group treated with Acthar vs the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function test B: Mean slope of volume expired in 1 second test</measure>
    <time_frame>36 weeks</time_frame>
    <description>Mean slope of volume expired in 1 second test decline from baseline in the group treated with Acthar vs the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function test C: Mean slope of negative inspiratory force test</measure>
    <time_frame>36 weeks</time_frame>
    <description>Mean slope of negative inspiratory force test decline from baseline in the group treated with Acthar vs the placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Summary of Columbia-Suicide Severity Rating Scale (C-SSRS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Acthar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar</intervention_name>
    <description>Repository corticotropin injection administered subcutaneously once a day</description>
    <arm_group_label>Acthar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo gel injection administered subcutaneously once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of clinically definite ALS, clinically probable-laboratory supported ALS,
             or clinically probable ALS based on revised El Escorial criteria.

          2. ALS symptom onset ≤ 2 years prior to the Screening Visit.

          3. On riluzole 50 mg twice a day for ≥ 4 weeks prior to the Screening Visit.

          4. Forced vital capacity (FVC) ≥ 60% at the Screening Visit.

          5. Systolic blood pressure ≤ 140 mm Hg and a mean diastolic blood pressure of ≤ 90 mm Hg
             at the Screening and Baseline Visits.

        Exclusion Criteria:

          1. History of use of adrenocorticotropic hormone (ACTH) preparations for treatment of
             ALS.

          2. Any medical condition known to have an association with motor neuron dysfunction
             (other than ALS) which might confound or obscure the diagnosis of ALS.

          3. Requires nocturnal continuous positive airway pressure or bilevel positive airway
             pressure.

          4. Tracheostomy, diaphragm pacing, or ongoing need for assisted ventilation of any type
             at Screening Visit.

          5. Known contraindication(s) to Acthar.

          6. History of chronic active hepatitis including active or chronic hepatitis B, or acute
             or chronic hepatitis C.

          7. History of tuberculosis (TB) infection, any signs/symptoms of TB, or any close
             contact with an individual with an active TB infection.

          8. Clinically significant infection requiring intravenous administration of antibiotics
             and hospitalization in the 4 weeks prior to the Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roman Bilyk</last_name>
    <phone>908-238-6755</phone>
    <email>roman.bilyk@mallinckrodt.com</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>March 1, 2017</lastchanged_date>
  <firstreceived_date>February 23, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
